申请人:HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
公开号:US11236059B2
公开(公告)日:2022-02-01
The present invention is directed to novel natural product-derived ratjadone-based compounds useful as payloads (or toxins) in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connection with drug conjugates. The present invention further relates to new ratjadone compositions including the aforementioned payloads, payload-linkers and drug conjugates, and methods for using these payloads, payload-linkers and drug conjugates, to treat pathological conditions including cancer, inflammatory and infectious diseases.
本发明涉及新型天然产物衍生的大鼠鸦胆子酮基化合物,该化合物可用作具有细胞靶标结合分子(CTBM)的药物共轭物构建体中的有效载荷(或毒素),以及与药物共轭物相关的有效载荷连接化合物。本发明进一步涉及包括上述有效载荷、有效载荷连接物和药物共轭物在内的新型鼠爪酮组合物,以及使用这些有效载荷、有效载荷连接物和药物共轭物治疗包括癌症、炎症和传染性疾病在内的病理条件的方法。